We review some recent developments regarding the concept of cardiometabolic syndrome and its relation with hypertension and overall cardiovascular disease risk. We emphasize how this new clinical entity has helped to understand multimorbidity in chronic diseases. This concept has important consequences for individual patient treatment as well as public health policy. The challenge derived from cardiovascular disease and other chronic conditions is increasing worldwide, but the highest burden is located in the developing world. Thus, new and cost-effective approaches are needed for diseases that are mainly occurring in the poorest and less educated populations. We illustrate this situation analyzing hypertension and cardiometabolic syndrome data derived from a recent national health survey in Chile.
Aguilar-Salinas, C.A. et al. (2004) High Prevalence of Metabolic Syndrome in Mexico. Arch Med Res35: 76—81.
2.
Alberti, K.G. and Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med15: 539—555.
3.
Arcaro, G. et al. (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation105: 576—582.
4.
Balkau, B. and Charles, M.A. (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med16: 442—453.
5.
Bergman, R.N. et al. (2007) Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med120(2 Suppl 1): S3—8.
6.
Cuspidi, C. et al. (2007) Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens20: 296—303.
7.
De Fronzo, R.A. et al. (1975) The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest55: 845—855.
8.
Despres, J.P. (2006) Is visceral obesity the cause of the metabolic syndrome?Ann Med38: 52—63.
9.
Despres, J.P. and Lemieux, I. (2006) Abdominal obesity and metabolic síndrome. Nature444: 881—887.
10.
Eckel, R.H. et al. (2005) The metabolic síndrome. Lancet365: 1415—1428.
11.
Einhorn, D. et al. (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract9: 237—252.
12.
Fasce, E. et al. (1992) La hipertensión arterial en una comunidad urbana de Chile. Rev Chil Cardiol11: 1—12.
13.
Ferrario, C.M. et al. (2002) The hypertension—lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis . Am J Med Sci323: 17—24.
14.
Grundy, S.M. et al. (2004) American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433—438.
15.
Guo, X. ( 2005) Hypertension genes are genetic markers for insulin sensitivity and resistance. Hypertension45: 799—803.
16.
Hall, J.E. et al. (1992) Obesity—associated hypertension. Hyperinsulinemia and renal mechanisms. Hypertension19(1 Suppl): 145—155.
17.
International Diabetes Federation (2005) The IDF consensus worldwide definition of the metabolic syndrome. Part 1: Worldwide definition for use in clinical practice. Available at http://www.idf.org/webdata/docs/Metabolic_Syndrome_Definition.pdf .
18.
Kahn, R. et al. (2005) American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care28: 2289—2330.
19.
Kaplan, N.M. (1989) The deadly quartet. Upper—body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med149: 1514—1522.
20.
Kempf, K. et al. (2006) Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann NY Acad Sci1084: 30—48.
21.
Kershaw, E.E. and Flier, J.S. (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab89: 2548—56.
22.
Kintschner, U. et al. (2007) Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Cardiovasc Diabetol36: 12.
23.
Kjeldsen, S.E. et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high—risk hypertensive patients: the VALUE trial. J Hypertens24: 1405—1412.
24.
Kunze, D.L. et al. (2007) Hypertension in sleep apnea: the role of the sympathetic pathway. Cleve Clin J Med74: S34—36.
25.
Lee, Y.H. and Pratley, R.E. (2005) The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep5: 70—75.
26.
Leslie, B.R. (2005) Metabolic syndrome: historical perspectivas. Am J Med Sci330: 264—268.
27.
Meisinger, C. et al. (2006) Metabolic syndrome: older than usually assumed, but still too young to die. Clin Chem52: 897—898.
28.
Minsal (2003) Encuesta Nacional de Salud, Chile 2003. Available at: http://epi.minsal.cl/epi/html/invest/ENS/ENS.htm.
29.
National Cholesterol Education Program (2001 ) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001)J Am Med Assoc285: 2486—2497.
30.
Negro, R. et al. (2004) Pioglitazone reduces blood pressure in non—dipping diabetic patients. Minerva Endocrinol29: 11—17.
31.
Negro, R. et al. (2005) Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract70: 20—25.
32.
Ong, K.L. et al. (2007) Prevalence, Awareness, Treatment, and Control of Hipertensión Among United Status Adults 1999—2004. Hypertension49: 69—75.
33.
Raikkonen, K. et al. (2007) Depressive symptoms and stressful life events predict metabolic syndrome among middle—aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care30: 872—877.
34.
Reaven, G. (1988) Role of insulin resistance in human disease. Diabetes37: 1595—1607.
35.
Reaven, G.M. (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med44: 121—123.
36.
Reaven, G.M. (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev75: 473—486.
37.
Reaven, G.M. (2005) The metabolic syndrome: requiescat in pace. Clin Chem51: 931—938.
38.
Reaven, G.M. (2006) The metabolic syndrome: is this diagnosis necessary?Am J Clin Nutr83: 1237—1247.
39.
Roberts, A.W. and Evans, M. (2004) The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetes. Curr Opin Lipidol15: 89—91.
40.
Sarafidis, P.A. and Nilsson, P.M. (2006) The metabolic syndrome: a glance at its history . J Hypertens24: 621—626.
41.
Simons, L.A. et al. (1998) Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis137: 197—203.
42.
Stout, R.W. (1991) Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. Am J Med90: 62S—65S.
Thomas, G.N. et al. (2000) Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese . Metabolism49: 1523—1528.
45.
WHO Collaborating Centre for Drug Statistics Methodology (2007) Available at: http://www.whocc.no/atcddd/atcsystem.html .
46.
Wofford, M.R. et al. (2004) Pathophysiology and treatment of obesity hypertension. Curr Pharm Des10: 3621—3637.
